![]() |
|
|
Vol. 286, Issue 2, 870-874, August 1998
Department of Physiology, Pharmacology and Toxicology, University of León, León, Spain
| |
Abstract |
|---|
|
|
|---|
Fiber formulations are used in human nutrition owing to their beneficial properties for health. It is probable that ingestion of fiber coincides with the oral administration of drugs, and a modification of its oral absorption, and therefore of its pharmacokinetics, can appear. In the present study, the compartmental and noncompartmental pharmacokinetic parameters of ethinylestradiol (EE) in rabbits after oral administration were determined. It was also studied whether the presence of two different fiber formulations [A, wheat bran (76.5%), fruit fiber (12%) and guar gum (2%) and B, Plantago ovata seeds (65%) and P. ovata seed cuticles (2.2%)] in the gastrointestinal tract modified the pharmacokinetics of EE when administered at the same time. Three groups of rabbits were used: control, fiber A and fiber B. The animals in all three groups received 1 mg/kg b. wt. EE. The estrogen was administered alone in the control group and in the presence of 4 g of fiber A and fiber B, respectively, in the other two groups. After compartmental (two-compartment open model) and noncompartmental analyses of plasma concentrations, statistical analysis revealed that the presence of fiber (both A and B) decreased between 29% and 35% the extent of EE absorbed (represented by the pharmacokinetic parameters area under the curve and the maximum plasma concentration) without affecting the rate of the absorption process (represented by the time to reach maximum concentration and the absorption rate constant).
| |
Introduction |
|---|
|
|
|---|
EE
is a synthetic estrogen that is widely used as a component of oral
contraceptives. This compound is also used in the treatment of
functional uterine bleeding and menopausal symptoms, for the inhibition
of lactation and for palliative treatment of breast cancer in
postmenopausal women and prostate cancer (Masterson, 1988
; Godsland
et al., 1992
).
In order to avoid its adverse effects, EE is used at low doses; in
particular, the dose of EE, when used for oral contraception, has been
reduced to 30 to 50 µg per day. When other drugs and/or foods are
administered at the same time, interactions may appear and EE blood
concentrations may be ineffective (Goldzieher, 1994
).
The bioavailability and disposition of oral medications are governed by
the processes of absorption and presystemic clearance, and these may be
influenced by the presence of certain diet components in the
gastrointestinal tract (Melander and McLean, 1983
). Dietary fiber is
widely accepted as an important part of healthy human nutrition, and
fiber formulations are marketed in the United States and Europe (Silk,
1989
; Scheppach et al., 1990
) with extensive advertising
campaigns directed to the consumer. This information shows these
products as highly effective in the treatment of obesity and
constipation prevention, for decreasing blood cholesterol and glucose
levels and even for preventing the development of gastrointestinal
cancer. These aspects induce the public to consume commercial fiber
preparations without medical control, in a continued and sometimes
abusive way. Under these circumstances, it is highly probable that
fiber ingestion coincides with oral administration of any drug, which
could modify its oral absorption and therefore its pharmacokinetics.
The influence of fiber on the presystemic clearance of drugs is most
likely to be clinically relevant with drugs having narrow therapeutic
margins (Melander and McLean, 1983
), e.g., EE.
Food intake can affect the absorption and bioavailability of several
drugs (Welling, 1977
; Melander and McLean, 1983
), but little
information is available regarding contraceptive steroids. Several
studies have shown that nutrition and specific dietary factors
influence the metabolism of steroid compounds, which are primarily
metabolized in the liver before their excretion in the urine or bile
(Anderson and Kappas, 1982
). An increase in the protein to carbohydrate
ratio in the diet of healthy subjects can increase estrogen
2-hydroxylation (Anderson, et al. 1984
), decrease androgen
5
-reduction (Kappas et al., 1983
), alter the plasma levels of testosterone and cortisol in a reciprocal fashion and
produce parallel changes in the binding globulin for these steroids
(Anderson et al., 1987
).
The purpose of the present study was to establish the compartmental and noncompartmental pharmacokinetic parameters of EE in rabbits after its oral administration and to determine whether the presence of two different fiber formulations in the gastrointestinal tract modifies the pharmacokinetics of EE when this drug and fiber formulations are administered at the same time.
| |
Methods |
|---|
|
|
|---|
Animals. Fifteen healthy, female New Zealand White rabbits weighing 2.9 to 3.5 kg were used. The animals were housed in individual metal cages, which allowed the isolation of feces in a lower container to avoid coprophagia. The environmental conditions were as follows: constant humidity (55 ± 10%), temperature (19 ± 2°C) and a 12-hr light/12-hr dark cycle. The animals were maintained on laboratory chow and water ad libitum, and they were fasted for ~24 hr before drug administration, with free access to water.
Materials. EE was obtained from Sigma Chemical Co. (St, Louis, MO), sodium pentobarbital from Barcia (Madrid, Spain), heparin from Rovi, S.A. (Madrid, Spain), fiber A from Kneipp-Werke (Würzburg, Germany) and fiber B from Madaus Cerafarm, S.A. (Barcelona, Spain). The fiber composition was as follows: for fiber A, wheat bran (76.5%), fruit fiber (12%) and guar gum (2%) (the rest of the composition appeared as excipients); for fiber B, Plantago ovata seeds (65%) and P. ovata seed cuticles (2.2%). As well, fiber B contained 18.1% saccharose, and the rest of the composition appeared as excipients.
Preparation of the experimental animals. Rabbits were anesthetized with sodium pentobarbital (30 mg/kg b. wt. i.v.), and the left carotid artery was cannulated with a silicone catheter [Silastic medical-grade tubing, 1.02 mm (inner diameter) × 2.16 mm (outer diameter)]. These cannulas were placed before the trial started. The end of the tubing was passed subcutaneously to emerge at the back of the neck. EE and fiber were administered to the conscious animals ~2 hr after the catheter was inserted.
Study design. Animals were randomly divided into three groups of five rabbits each: control, fiber A and fiber B and received the respective following preparations: 1 mg/kg EE p.o., 1 mg/kg EE p.o. and 4 g fiber A p.o. and 1 mg/kg EE p.o. and 4 g fiber B p.o. The five rabbits of the control group received 1 mg/kg EE orally as a solution (1 ml) in a mixture of water and ethanol (4:1, v/v). Likewise, the 10 rabbits of groups A and B were orally treated with EE, but immediately before EE administration, they received 4 g p.o. of fiber A and B, respectively, dispersed in water. Both the EE and fiber solutions were administered by gastric intubation. A total of 50 ml water was used for fiber administration and cannula cleaning.
Blood sampling.
Blood samples (3 ml) were collected through
the carotid artery canula before and at 5, 10, 20, 30, 60, 90, 120, 150, 180 and 240 min after EE administration into heparinized
containers. Immediately after collection, plasma was separated by
centrifugation and stored at
20°C until analyzed.
Plasma concentration of EE.
EE plasma concentrations were
determined by high-performance liquid chromatography with
electrochemical detection according to the method previously described
by Fernandez et al. (1993)
. Intraday and interday accuracy
and precision were within 10%.
Pharmacokinetic analysis. Pharmacokinetic analysis was performed on the basis of a compartmental as well a noncompartmental description of the observed data. For compartmental analysis, plasma EE concentration-time profiles were individually fitted to the following exponential equation:
|
i is the slope of each
of n first-order rate processes, e is the exponential
function (base e) and t is time. The estimates of
Ci and
i were
calculated by using a computer program based on the nonlinear,
iterative, least-squares regression analysis PCNONLIN 3.0 (Metzler and
Weiner, 1989
) was calculated by
least-squares regression of the logarithm of plasma concentration versus time curve over the terminal elimination phase.
The area under the plasma concentration-time curve from time zero to
the last determined sample time
(AUC0
t) was calculated by the
trapezoidal rule, and the total area under the plasma AUC was
determined by adding AUC0
t to the
residual area AUCt-
(calculated from
Ct, the last experimental plasma
concentration divided by the terminal slope
).
The total body clearance was calculated by dividing the dose by the
AUC. The half-life associated with the
phase
(t1/2
) was calculated from the
quotient 0.693/
. Maximum plasma EE concentration (Cmax) and the time to reach maximum
concentration (tmax) were read directly
from the individual plasma concentration-time curves.
Statistical evaluation.
All pharmacokinetic parameters were
calculated for each animal and the data presented as arithmetic
means ± S.D. The data obtained from the three groups were
compared for statistical significance by using the one-way analysis of
variance, and Duncan's test was used to evaluate differences between
data stets when the results were significant. A P
.05 was taken
as the level of significance for all analyses.
| |
Results |
|---|
|
|
|---|
Figure 1 shows the plot of the mean plasma concentrations of EE as a function of time after oral administration of 1 mg/kg EE for the three groups studied. This figure shows that the mean plasma concentrations of EE were higher in the control rabbits than in the fiber A and fiber B groups. The values of the pharmacokinetic parameters determined by both compartmental and noncompartmental analyses are given in tables 1 and 2, respectively.
|
|
|
After compartmental analysis, the plasma concentration-time curves were
best resolved in all experiments into a two-compartment open model. The
EE pharmacokinetic parameters determined by compartmental analysis are
given in table 1. The values obtained for
ka were very similar in the control group
(0.151 min
1) and in both A (0.156 min
1) and B (0.167 min
1) groups. The values obtained for AUC
were 1.4 times higher in the control group (602.47 ng·min·ml
1) than in the A group
(428.44 ng·min·ml
1) and ~1.5 times
higher than in the B group (398.19 ng·min·ml
1).
Cmax values were also higher in the control
group (14.487 ng·ml
1) than in A (10.368 ng·ml
1) and B (9.501 ng·ml
1) groups. With regard to the most
representative parameter values of bioavailability, AUC,
Cmax and tmax
(Ritchel, 1987
; McGilveray et al., 1990
), no significant
differences were found for tmax (9.489 min
in the control group, 8.570 min in group A and 8.522 in group B), but
there were significant differences for Cmax
and AUC values between the control group and groups A and B.
ka values ranged from 0.1510 min
1 (control group) to 0.1670 min
1 (B group) and
-values from 0.0166 min
1 (A and B groups) to 0.0171 min
1 (control group). There were no
significant differences when these parameters, representative of
absorption and elimination rates, were compared.
The pharmacokinetic parameters derived from noncompartmental analysis
are shown in table 2. In this case, AUC values were also higher in the
control group (628.67 ng·min·ml
1) than
in A (436.60 ng·min·ml
1) and B (418.60 ng·min·ml
1) groups. Similar results
were obtained for Cmax: 16.33 ng·ml
1 (control), 11.35 ng·ml
1 (A group) and 10.61 ng·ml
1 (B group). The
tmax value was 10 min in all three groups.
Statistical analysis revealed no significant differences for
tmax values but significant differences for
AUC and Cmax when these parameters were
compared between the control group and groups A and B.
-values were
similar to
-values obtained after compartmental analysis.
| |
Discussion |
|---|
|
|
|---|
In a previous study performed in rabbits (Fernández et
al., 1996
), the pharmacokinetics of EE after intravenous
administration was also best described by a two-compartment open model.
Hümpel et al. (1979)
considered EE to behave as a
three-compartment open model after an intravenous dose and as a
two-compartment model after oral dosing. Furthermore, Goldzieher in
1994, in a revision about this theme, indicated that in most cases the
pharmacokinetics of EE after both oral and intravenous administration
was best described by a two-compartment open model.
Düsterberg et al., in a study carried out in 1986 in
rabbits and with the same dose of EE (1 mg/kg) in a microcrystalline suspension administered by the oral route, found a
tmax value of 15 min, which is similar to
our data (10 min). However, these authors reported values for
Cmax (2.53 ± 3.8 ng·ml
1) and AUC (78 ± 108 ng·min·ml
1) that were lower than those
shown in this study (16.33 ± 3.62 ng·ml
1 and 628.67 ± 136.77 ng·min·ml
1, respectively). With regard
to studies in women, peak concentrations of EE after a variety of doses
were reached later, between 120 and 240 min after dosing (Goldzieher,
1994
).
Studies of fiber-drug interactions are scarce, as indicated by
Kritchevsky (1988)
and Eastwood (1992)
in two revisions performed on
this subject. The results obtained in these studies were variable. Thus, Richter et al. (1991)
showed that the consumption of a
soluble fiber with pectin caused a decrease in the intestinal
absorption of the hypolipidemic agent lovastatin. Retuert and
Yazdani-Pedram (1992)
found that fiber (especially
carboxymethylcellulose) induces the decomposition of other drugs like
diethylpropion hydrochloride. On the other hand, Astarola et
al. (1992)
found higher levels of L-dopa when
administered with an insoluble fiber that contained wheat bran.
However, Uusitupa et al. (1990)
did not find any alteration in the absorption of glibenclamide when this drug was administered with
guar gum.
With regard to interactions between fiber and estrogens, in recent years many studies have suggested that dietary components like fiber and fat may play a role in the regulation of the enterohepatic metabolism of these compounds, in this way influencing the estrogen levels in the body. Nevertheless, we have not found any studies about the modification of the oral absorption of EE in the presence of fiber.
Several studies suggest that fiber-rich food has a reducing effect on
estrogen levels in the blood and urine. Vegetarian diets tend to
contain less fat and more fiber than nonvegetarian diets, and these
differences appear to influence the metabolism of endogenous estrogens
(Howie and Shultz, 1985
) and/or the reabsorption of biliary estrogens
(Goldin et al., 1982
; Adlercreutz et al., 1986
). A comparison of the plasma steroid levels between omnivorous and vegetarian men has indicated that estradiol concentrations were lower
in the vegetarian group (Howie and Shultz, 1985
). However, Fotherby
(1990)
indicates that whether metabolism of contraceptive steroids
differs between vegetarians and nonvegetarians is still controversial.
In many of the situations discussed above, changes occur in serum SHBG
concentrations, which were increased in vegetarians. Adlercreutz
et al. (1987)
indicated that in the presence of lignan precursors and phytoestrogens in fiber-rich vegetables, legumes and
grain, a diet rich in fiber may stimulate SHBG synthesis in the liver
and may in this way reduce the levels of free estradiol and
testosterone in the plasma. However, these changes will not affect EE,
which does not bind to SHBG (Akpoviroro et al., 1981
).
A type of drug-nutrient interaction involves food as a mechanical
barrier that prevents drug access to mucosal surfaces. This interaction
results in decreased drug absorption and a shortened duration of action
(Kirk, 1995
). A meal may also influence the bioavailability by the
direct binding of drugs by substances in food or by altering luminal
pH, gastric emptying, intestinal transit, mucosal absorption,
splanchnic-hepatic blood flow and metabolism of the drug (Anderson,
1988
). In the present study we found that the presence of fiber (both
P. ovata and a mixture of wheat bran, fruit fiber and guar
gum) modified the extent of EE absorbed (represented by the
pharmacokinetic parameters AUC and Cmax)
without affecting the rate of the absorption process (represented
by ka and
tmax). Taking into account that
Cmax and AUC are the only parameters that
are modified, we think that fiber acts as a mechanical barrier that
prevents EE access to mucosal surfaces, resulting in decreased drug
absorption and a shortened duration of action.
| |
Footnotes |
|---|
Accepted for publication April 8, 1998.
Received for publication November 5, 1997.
Send reprint requests to: Nélida Fernández, Department of Physiology, Pharmacology and Toxicology, Campus Vegazana s/n, University of Leon, 24071-Leon, Spain.
| |
Abbreviations |
|---|
EE, ethinylestradiol SHBG, sex hormone-binding
globulin;
and
, apparent first-order disposition rate constants;
A and B,
and
zero-time intercepts, respectively;
ka, absorption rate constant;
k10, apparent first-order elimination rate
constant from the central compartment;
k12, apparent first-order transfer rate constant from the central
compartment to the peripheral compartment ;
k21, apparent first-order transfer rate
constant from the peripheral compartment to the central compartment ;
AUC, area under the plasma concentration-time curve;
Cmax, maximum plasma concentration;
tmax, time to reach maximum concentration;
t1/2
, half-life associated with
-phase;
t1/2
, half-life
associated with
-phase;
t1/2ka, absorption half-life;
t1/2k10, elimination
from the central compartment half-life;
, noncompartmental apparent
first-order disposition rate constant;
t1/2
, half-life associated with
phase;
AUCt
, AUC from the last
experimental time to infinity.
| |
References |
|---|
|
|
|---|
1-
-reduction of testosterone and the cytochrome P-450-dependent oxidation of estradiol by dietary macronutrients in man.
Proc Natl Acad Sci USA
80:
7646-7649
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||